Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Position Increased by Royce & Associates LP

Royce & Associates LP increased its stake in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 5.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 958,885 shares of the company’s stock after buying an additional 50,107 shares during the quarter. Royce & Associates LP owned about 0.38% of Maravai LifeSciences worth $5,226,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in MRVI. JPMorgan Chase & Co. boosted its holdings in shares of Maravai LifeSciences by 1,172.4% during the third quarter. JPMorgan Chase & Co. now owns 4,050,245 shares of the company’s stock valued at $33,658,000 after acquiring an additional 3,731,924 shares during the period. Point72 DIFC Ltd bought a new position in Maravai LifeSciences in the 3rd quarter worth about $22,108,000. Quantinno Capital Management LP increased its stake in shares of Maravai LifeSciences by 610.2% in the third quarter. Quantinno Capital Management LP now owns 336,527 shares of the company’s stock valued at $2,797,000 after purchasing an additional 289,141 shares during the period. Monaco Asset Management SAM increased its stake in shares of Maravai LifeSciences by 288.5% in the fourth quarter. Monaco Asset Management SAM now owns 291,364 shares of the company’s stock valued at $1,588,000 after purchasing an additional 216,364 shares during the period. Finally, Systematic Financial Management LP raised its holdings in shares of Maravai LifeSciences by 14.7% during the third quarter. Systematic Financial Management LP now owns 1,612,161 shares of the company’s stock valued at $13,397,000 after buying an additional 206,499 shares during the last quarter. 50.25% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Maravai LifeSciences

In related news, General Counsel Kurt Oreshack sold 25,000 shares of Maravai LifeSciences stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $5.03, for a total value of $125,750.00. Following the transaction, the general counsel now owns 167,618 shares of the company’s stock, valued at approximately $843,118.54. This trade represents a 12.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.63% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

MRVI has been the topic of several analyst reports. Bank of America lowered their target price on Maravai LifeSciences from $9.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, March 3rd. Robert W. Baird cut shares of Maravai LifeSciences from an “outperform” rating to a “neutral” rating and cut their price objective for the company from $9.00 to $3.00 in a research note on Wednesday, February 26th. Baird R W lowered shares of Maravai LifeSciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 26th. Guggenheim started coverage on shares of Maravai LifeSciences in a research report on Thursday, December 19th. They set a “neutral” rating on the stock. Finally, The Goldman Sachs Group cut shares of Maravai LifeSciences from a “neutral” rating to a “sell” rating and decreased their price objective for the company from $7.00 to $4.25 in a report on Thursday, December 5th. One analyst has rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, Maravai LifeSciences presently has a consensus rating of “Hold” and a consensus target price of $9.28.

Maravai LifeSciences Price Performance

NASDAQ MRVI opened at $2.43 on Thursday. The stock has a market capitalization of $613.64 million, a P/E ratio of -1.48 and a beta of -0.08. The company has a debt-to-equity ratio of 0.89, a quick ratio of 9.94 and a current ratio of 10.74. The business’s fifty day moving average is $4.09 and its two-hundred day moving average is $5.90. Maravai LifeSciences Holdings, Inc. has a 1 year low of $2.25 and a 1 year high of $11.56.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.